Clinical trials: Optical Neuritis
NMO Spectrum Disorder, MRI
Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
CLUE is a prospective study to assess structural and functional changes of the brain, spinal cord, and optic nerve, as well as the inflammatory environment in patients with neuroinflammatory and demyelinating diseases.
- Conditions
- NMO Spectrum Disorder, MRI, Multiple Sclerosis, MOGAD
- Trial name
- NCT04106830
- Testing
- Intravenous steroid
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
Demyelinating Diseases, Multiple Sclerosis
Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve
The goal of this observational study is to longitudinally investigating subjects with inaugural acute optic neuritis (ON). The main questions it aims to answer are: Does the time to corticosteroid treatment affect the visual…
- Conditions
- Demyelinating Diseases, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Attack, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
- Trial name
- ACON (NCT05605951)
- Testing
- non-interventional study
- Where
- 26 sites in United States, Argentina and 15 more
- Volunteers
- 200 people
- Sponsor
- Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecul
Neuromyelitis Optica Spectrum Disorder Attack
Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder
Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, inflammatory autoimmune disorder of the central nervous system characterized by the pathogenic anti-aquaporin 4 antibody (AQP4-IgG).
- Trial name
- EASE-NMO (NCT07184840)
- Testing
- Intravenous Methylprednisolone (IVMP), Complement protein C5 inhibitor
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Tianjin Medical University General Hospital
Neuromyelitis Optica
Safety and Tolerability of Rituximab in Neuromyelitis Optica
The goal of this research study is to investigate whether Rituximab is safe to use in patients suffering from NMO, or who are at high risk for developing NMO.
- Trial name
- NCT00501748
- Testing
- Rituximab
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Optic Neuritis
Epidemiologic and Clinical Characteristics of Optic Neuritis in China
This will be a hospital-based retrospective multi-center study on epidemiologic and clinical characteristics of optic neuritis among Chinese. The investigation will cover about 29 provinces or municipalities all around China.
- Trial name
- NCT04257734
- Testing
- observation
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chinese PLA General Hospital
Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis
Central Pain Study for ABX-1431
This study will determine the safety and tolerability of ABX-1431 in patients with central pain when added on to background pain therapy.
- Conditions
- Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis, Multiple Sclerosis, Longitudinally Extensive Transverse Myelitis
- Trial name
- NCT03138421
- Testing
- ABX-1431 HCl
- Where
- 2 sites in United Kingdom
- Volunteers
- 9 people
- Sponsor
- Abide Therapeutics
Optic Neuritis
Optical Coherence Tomography and Optic Neuritis Not Related to Multiple Sclerosis
The visual prognosis of optic neuritis not related to multiple sclerosis is unknown, both in terms of functional recovery and evolution.
- Trial name
- OCTON2 (NCT03963310)
- Where
- France
- Volunteers
- 38 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Neuromyelitis Optica Spectrum Disorders (NMOSD)
HANDLE-a Real World Study on Satralizumab in NMOSD
This study is a single-center, retrospective-prospective, non-interventional cohort study to assess the clinical outcomes of Chinese NMOSD patients treated with satralizumab in a real-world patient management model by collecting…
- Trial name
- NCT06829524
- Testing
- Satralizumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Huashan Hospital
Progressive Multiple Sclerosis, Neuromyelitis Optica.
Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica
Multiple sclerosis (MS) has been classically regarded as a chronic inflammatory autoimmune demyelinating disease of the central nervous system, along with a considerable pathological heterogeneity.
- Trial name
- NCT01364246
- Testing
- human umbilical cord mesenchymal stem cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Beike Bio-Technology Co., Ltd.
NMOSD, Neuromyelitis Optica Spectrum Disorder
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
The primary objective of this study is to confirm the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of ravulizumab in the treatment of Chinese adults with anti-aquaporin-4 (AQP4) antibody (Ab)…
- Trial name
- NCT07557420
- Testing
- Ravulizumab
- Where
- 10 sites in China
- Volunteers
- 19 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Neuromyelitis Optica Spectrum Disorders
An Open Label Study of the Effects of SHR1459 in NMOSDs Patients
This is an open-label study, to evaluate the efficacy and safety of SHR1459 in participants with NMOSDs.
- Trial name
- NCT04670770
- Testing
- Drug - SHR1459
- Where
- 8 sites in China
- Volunteers
- 10 people
- Sponsor
- Reistone Biopharma Company Limited
Optic Neuritis
Optic Neuritis Recovery After Oral or IV Corticosteroids
Patients aged 18-65 with acute demyelinating optic neuritis where treatment with high dose corticosteroids are already been chosen by the patient and the diagnosing physician will be contacted for screening and enrollment.
- Trial name
- NCT01524250
- Testing
- corticosteroids
- Where
- 2 sites in Canada
- Volunteers
- 51 people
- Sponsor
- London Health Sciences Centre
Acute Autoimmune Inflammatory Optic Neuritis
Repetitive Transorbital Alternating Current Stimulation in Acute Autoimmune Optic Neuritis
Optic neuritis (ON) is an acute inflammatory, demyelinating attack of the optic nerve that triggers neurodegeneration in the entire visual pathway; translating into visual dysfunction.
- Trial name
- ACSON (NCT03862313)
- Testing
- active-rtACS treatment
- Where
- Switzerland
- Volunteers
- 2 people
- Sponsor
- University of Zurich
Ultomiris-exposed Pregnant/ Postpartum, Pregnancy
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of…
- Conditions
- Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS)
- Trial name
- NCT06312644
- Testing
- Ultomiris
- Where
- 7 sites in United States, Australia and 5 more
- Volunteers
- 75 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Neuromyelitis Optica Spectrum Disorder
A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
This multicenter, single-arm, open-label study will evaluate the long-term safety and efficacy of satralizumab in participants with neuromyelitis optica spectrum disorder (NMOSD) who completed open-label extension (OLE) period of…
- Trial name
- NCT04660539
- Testing
- satralizumab, azathioprine (AZA), mycophenolate mofetil (MMF)
- Where
- 53 sites in United States, Bulgaria and 16 more
- Volunteers
- 119 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
MS-ResearchBiomarkerS
This study is being conducted to investigate risk factors for disability progression in Multiple Sclerosis and related disorders (MSRD).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- MS-ReBS (NCT05204459)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders
Evaluation of the Impact of Multiple Sclerosis and Its Treatments on Women Fertility
CONTEXT A desire for pregnancy is common in young patients with multiple sclerosis (MS). The impact of MS on women fertility is debated, and the impact of disease-modifying therapies (DMTs) on fertility is not well known.
- Conditions
- Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, Fertility
- Trial name
- FERTIMUS (NCT07164924)
- Testing
- blood sample to analyse AMH level on the serum
- Where
- 27 sites in France, Martinique
- Volunteers
- 800 people
- Sponsor
- University Hospital, Clermont-Ferrand
Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Generalized
Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
This is an open label, single-site, dose-escalation study in up to 25 participants with refractory autoimmune diseases of nervous system.
- Conditions
- Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Generalized, Multiple Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Trial name
- NCT06485232
- Testing
- Universal BCMA CAR-T, Universal CD19 CAR-T, Universal BCMA CAR-T; Universal CD19 CAR-T
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Xuanwu Hospital, Beijing
Multiple Sclerosis, NMO Spectrum Disorder
Epidemiological Characteristics of COVID-19 in Patients With MS or NMO
The purpose of this study is to collect French medical data for patients with Multiple Sclerosis (MS) or NeuroMyelitis Optica (NMO) spectrum disorder who are diagnosed or strongly suspected of being infected with Covid19.
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, COVID-19
- Trial name
- COVISEP (NCT04355611)
- Testing
- Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2)
- Where
- France
- Volunteers
- 2,465 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Neuromyelitis Optica Spectrum Disorder (NMOSD)
A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients
The purpose of this study is to evaluate the efficacy and safety of IMC-002 in the treatment of NMOSD.
- Trial name
- NCT06557174
- Testing
- IMC-002, mycophenolate mofetil， MMF
- Volunteers
- 116 people
- Sponsor
- ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.